Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
05 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-results-of-global-multicenter-enrgy-study-evaluating-zenocutuzumab-zbco-bizengri-in-nrg1-cancer-302369431.html
09 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/barda-and-partner-therapeutics-continue-partnership-around-development-of-leukine-sargramostim-rhu-gm-csf-to-potentially-improve-patient-care-for-sepsis-302347356.html
03 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/partner-therapeutics-leukine-sargramostim-receives-approval-in-japan-to-treat-autoimmune-pulmonary-alveolar-proteinosis-apap-302107763.html
17 Jan 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/comprehensive-review-highlights-importance-of-leukine-in-combination-with-anti-gd2-immunotherapy-for-treatment-of-high-risk-pediatric-neuroblastoma-302037532.html
20 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/exploratory-results-suggest-the-potential-role-of-leukine-as-a-host-directed-immunomodulator-302020419.html
15 Dec 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/partner-therapeutics-announces-publication-of-a-retrospective-cohort-review-of-15-leukine-treated-patients-with-pediatric-malignancies-and-invasive-fungal-disease-refractory-to-antifungal-therapy-301704560.html
Details:
The collaboration aims to fund a phase 2 in sepsis to assess the safety and enable dose selection of LEUKINE (sargramostim), a glycosylated recombinant human granulocyte-macrophage CSF.
Lead Product(s): Sargramostim
Therapeutic Area: Infections and Infectious Diseases Brand Name: Leukine
Study Phase: Phase IIProduct Type: Protein
Sponsor: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2025
Lead Product(s) : Sargramostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : BARDA
Deal Size : Undisclosed
Deal Type : Collaboration
BARDA, Partner Therapeutics Develop LEUKINE® for Sepsis Care Improvement
Details : The collaboration aims to fund a phase 2 in sepsis to assess the safety and enable dose selection of LEUKINE (sargramostim), a glycosylated recombinant human granulocyte-macrophage CSF.
Product Name : Leukine
Product Type : Protein
Upfront Cash : Undisclosed
January 09, 2025
Details:
Leukine (sargramostim) is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in yeast.
Lead Product(s): Sargramostim
Therapeutic Area: Oncology Brand Name: Leukine
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2022
Partner Therapeutics Announces Publication of a Retrospective Cohort Review of 15 LEUKINE® Treate...
Details : Leukine (sargramostim) is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in yeast.
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
December 15, 2022
Details:
People with Down syndrome are at higher risk for Alzheimer’s, and showed that GM-CSF improves cognition and brain pathology in AD mice and that Leukine® (sargramostim, glycosylated, yeast-derived rhuGM-CSF) improved cognition and reduced blood biomarkers of neuronal damage.
Lead Product(s): Sargramostim
Therapeutic Area: Neurology Brand Name: Leukine
Study Phase: PreclinicalProduct Type: Protein
Sponsor: University of Colorado
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2022
Lead Product(s) : Sargramostim
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : University of Colorado
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : People with Down syndrome are at higher risk for Alzheimer’s, and showed that GM-CSF improves cognition and brain pathology in AD mice and that Leukine® (sargramostim, glycosylated, yeast-derived rhuGM-CSF) improved cognition and reduced blood biomark...
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2022
Details:
Safety and efficacy of inhaled sargramostim for the treatment of COVID-19 has not been established and sargramostim is not approved for treatment of COVID-19. Sargramostim has a different mechanism of action from recombinant G-CSFs products and data should not be extrapolated.
Lead Product(s): Sargramostim
Therapeutic Area: Infections and Infectious Diseases Brand Name: Leukine
Study Phase: Phase IVProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 28, 2021
Lead Product(s) : Sargramostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Second Randomized Trial of Leukine® (sargramostim) in COVID-19 Demonstrates Improvement in Lung F...
Details : Safety and efficacy of inhaled sargramostim for the treatment of COVID-19 has not been established and sargramostim is not approved for treatment of COVID-19. Sargramostim has a different mechanism of action from recombinant G-CSFs products and data shou...
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
June 28, 2021
Details:
This study will evaluate the role of Leukine in reducing progression and need for hospitalization in COVID-19 patients. Primary study endpoints are: COVID-19-related emergency room visit, COVID-19- related hospitalization, or death.
Lead Product(s): Sargramostim
Therapeutic Area: Infections and Infectious Diseases Brand Name: Leukine
Study Phase: Phase IVProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2021
Lead Product(s) : Sargramostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This study will evaluate the role of Leukine in reducing progression and need for hospitalization in COVID-19 patients. Primary study endpoints are: COVID-19-related emergency room visit, COVID-19- related hospitalization, or death.
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
April 29, 2021
Details:
Data showed that five days of inhaled sargramostim plus standard of care (SOC) treatment improved oxygenation in patients, thereby meeting the primary endpoint.
Lead Product(s): Sargramostim
Therapeutic Area: Infections and Infectious Diseases Brand Name: Leukine
Study Phase: Phase IVProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2021
Lead Product(s) : Sargramostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SARPAC Clinical Trial of Leukine® in Hospitalized COVID-19 Patients Meets Primary Endpoint of Sig...
Details : Data showed that five days of inhaled sargramostim plus standard of care (SOC) treatment improved oxygenation in patients, thereby meeting the primary endpoint.
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
February 26, 2021
Details:
SARPAC Clinical Trial of Leukine® met the primary endpoint of improved oxygenation after five days of treatment with inhaled sargramostim in combination with standard of care (SOC) compared with SOC alone.
Lead Product(s): Sargramostim
Therapeutic Area: Infections and Infectious Diseases Brand Name: Leukine
Study Phase: Phase IVProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2021
Lead Product(s) : Sargramostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARPAC Clinical Trial of Leukine® met the primary endpoint of improved oxygenation after five days of treatment with inhaled sargramostim in combination with standard of care (SOC) compared with SOC alone.
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
February 26, 2021
Details:
The trial will evaluate the effectiveness of Leukine compared to a matched control cohort of G-CSF treated patients, as well as evaluate the immune reconstitution profile of the treated patients compared to a contemporaneous cohort of 20 patients who receive G-CSF.
Lead Product(s): Sargramostim
Therapeutic Area: Oncology Brand Name: Leukine
Study Phase: Phase IIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 06, 2020
Partner Therapeutics Starts Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched H...
Details : The trial will evaluate the effectiveness of Leukine compared to a matched control cohort of G-CSF treated patients, as well as evaluate the immune reconstitution profile of the treated patients compared to a contemporaneous cohort of 20 patients who rec...
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
November 06, 2020
Details:
First patient has been enrolled in the iLeukPulm clinical trial, a randomized phase 2 study of inhaled Leukine in hospitalized COVID-19 patients with acute hypoxemia.
Lead Product(s): Sargramostim
Therapeutic Area: Infections and Infectious Diseases Brand Name: Leukine
Study Phase: Phase IIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 25, 2020
Lead Product(s) : Sargramostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine® (rhu...
Details : First patient has been enrolled in the iLeukPulm clinical trial, a randomized phase 2 study of inhaled Leukine in hospitalized COVID-19 patients with acute hypoxemia.
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
August 25, 2020
Details:
Company to initiate an investigator-initiated randomized, double-blind, placebo-controlled clinical trial of Leukine(sargramostim, rhu-GM-CSF) in patients with acute respiratory failure associated with COVID-19, conducted at Singapore General Hospital.
Lead Product(s): Sargramostim
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Leukine
Study Phase: Phase IIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2020
Lead Product(s) : Sargramostim
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company to initiate an investigator-initiated randomized, double-blind, placebo-controlled clinical trial of Leukine(sargramostim, rhu-GM-CSF) in patients with acute respiratory failure associated with COVID-19, conducted at Singapore General Hospital.
Product Name : Leukine
Product Type : Protein
Upfront Cash : Inapplicable
May 28, 2020
ABOUT THIS PAGE
Partner Therapeutics is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Hydroxy Echinocandin bulk with DMF offered by Partner Therapeutics